-
Mashup Score: 5
John H. Strickler, MD, discusses treatment with telisotuzumab adizutecan for CRC as well as this ADC’s potential to broaden the CRC treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6
John H. Strickler, MD, discusses treatment with telisotuzumab adizutecan for CRC as well as this ADC’s potential to broaden the CRC treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The c-Met–targeted antibody-drug conjugate telisotuzumab adizutecan is at the forefront of a potential new era in CRC management. @DukeCancer #crcsm #oncology https://t.co/GFeU23YcVh https://t.co/sKZlvIHn3T
-
-
Mashup Score: 9
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC #crcsm #oncology https://t.co/qDTEDkzCDb
-
-
Mashup Score: 9
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC #crcsm #oncology https://t.co/qDTEDkzCDb
-
-
Mashup Score: 2
Japan’s Ministry of Health, Labour, and Welfare approved fruquintinib in metastatic colorectal cancer following progression with chemotherapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Japan’s MHLW Approves Fruquintinib in Pretreated mCRC After Chemotherapy #crcsm #oncology https://t.co/1E3Z2XibLr
-
-
Mashup Score: 2GCC19CART Is Safe, Shows Clinical Activity in GCC+ R/R Metastatic Colorectal Cancer - 3 month(s) ago
The CAR T-cell therapy GCC19CART was safe and showed clinical activity in relapsed/refractory metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
GCC19CART Is Safe, Shows Clinical Activity in GCC+ R/R Metastatic Colorectal Cancer #crcsm #oncology https://t.co/mXLkLqb05x
-
-
Mashup Score: 2
Japan’s Ministry of Health, Labour, and Welfare approved fruquintinib in metastatic colorectal cancer following progression with chemotherapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Japan’s MHLW Approves Fruquintinib in Pretreated mCRC After Chemotherapy #crcsm #oncology https://t.co/1E3Z2XibLr
-
-
Mashup Score: 2
Japan’s Ministry of Health, Labour, and Welfare approved fruquintinib in metastatic colorectal cancer following progression with chemotherapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Japan’s MHLW Approves Fruquintinib in Pretreated mCRC After Chemotherapy #crcsm #oncology https://t.co/1E3Z2XibLr
-
-
Mashup Score: 0GCC19CART Is Safe, Shows Clinical Activity in GCC+ R/R Metastatic Colorectal Cancer - 3 month(s) ago
The CAR T-cell therapy GCC19CART was safe and showed clinical activity in relapsed/refractory metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
GCC19CART Is Safe, Shows Clinical Activity in GCC+ R/R Metastatic Colorectal Cancer #crcsm #oncology https://t.co/mXLkLqb05x
-
-
Mashup Score: 0
The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued. #crcsm #oncology https://t.co/slhElwj6K9
-
The c-Met–targeted antibody-drug conjugate telisotuzumab adizutecan is at the forefront of a potential new era in CRC management. @DukeCancer #crcsm #oncology https://t.co/GFeU23YcVh https://t.co/sKZlvIHn3T